Barclays Maintains Overweight on Globus Medical, Raises Price Target to $123
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $118 to $123.
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $118 to $123.